Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56


Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer.

Braman N, Prasanna P, Whitney J, Singh S, Beig N, Etesami M, Bates DDB, Gallagher K, Bloch BN, Vulchi M, Turk P, Bera K, Abraham J, Sikov WM, Somlo G, Harris LN, Gilmore H, Plecha D, Varadan V, Madabhushi A.

JAMA Netw Open. 2019 Apr 5;2(4):e192561. doi: 10.1001/jamanetworkopen.2019.2561.


Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.

Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr.

Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28.


Prechemotherapy Education: Reducing Patient Anxiety Through Nurse-Led Teaching Sessions

Apor E, Connell NT, Faricy-Anderson K, Barth P, Youssef R, Fenton M, Sikov WM, Thomas A, Rosati K, Schumacher A, Lombardo A, Korber S, Khurshid H, Safran H, Mega A.

Clin J Oncol Nurs. 2018 Feb 1;22(1):76-82. doi: 10.1188/18.CJON.76-82.


Which patients with early-stage triple-negative breast cancer should receive a platinum?

Sikov WM.

Clin Adv Hematol Oncol. 2017 Jul;15(7):510-514. No abstract available.


A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I.

Pachman DR, Dockter T, Zekan PJ, Fruth B, Ruddy KJ, Ta LE, Lafky JM, Dentchev T, Le-Lindqwister NA, Sikov WM, Staff N, Beutler AS, Loprinzi CL.

Support Care Cancer. 2017 Nov;25(11):3407-3416. doi: 10.1007/s00520-017-3760-2. Epub 2017 May 27.


Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study.

Schumacher A, Sikov WM, Quesenberry MI, Safran H, Khurshid H, Mitchell KM, Olszewski AJ.

PLoS One. 2017 Feb 24;12(2):e0172957. doi: 10.1371/journal.pone.0172957. eCollection 2017.


Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.

Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D.

JAMA Oncol. 2017 Aug 1;3(8):1043-1050. doi: 10.1001/jamaoncol.2016.6749.


Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).

Ollila DW, Cirrincione CT, Berry DA, Carey LA, Sikov WM, Hudis CA, Winer EP, Golshan M.

J Am Coll Surg. 2017 Apr;224(4):688-694. doi: 10.1016/j.jamcollsurg.2016.12.036. Epub 2017 Jan 13.


Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy.

Bychkovsky BL, Dizon DS, Sikov WM.

Clin Obstet Gynecol. 2016 Dec;59(4):756-771. Review.


Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).

Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B, Henry NL, Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW; Alliance for Clinical Trials in Oncology.

Breast Cancer Res Treat. 2016 Nov;160(2):297-304. Epub 2016 Oct 4.


Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).

Warner ET, Ballman KV, Strand C, Boughey JC, Buzdar AU, Carey LA, Sikov WM, Partridge AH.

Breast Cancer Res Treat. 2016 Aug;159(1):109-18. doi: 10.1007/s10549-016-3918-5. Epub 2016 Jul 22.


SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN.

Breast Cancer Res Treat. 2016 Aug;158(3):485-95. doi: 10.1007/s10549-016-3889-6. Epub 2016 Jul 8.


Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.

Brodsky AS, Xiong J, Yang D, Schorl C, Fenton MA, Graves TA, Sikov WM, Resnick MB, Wang Y.

BMC Cancer. 2016 Apr 18;16:274. doi: 10.1186/s12885-016-2302-5.


Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.

Varadan V, Gilmore H, Miskimen KL, Tuck D, Parsai S, Awadallah A, Krop IE, Winer EP, Bossuyt V, Somlo G, Abu-Khalaf MM, Fenton MA, Sikov W, Harris LN.

Clin Cancer Res. 2016 Jul 1;22(13):3249-59. doi: 10.1158/1078-0432.CCR-15-2021. Epub 2016 Feb 3.


Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015.

Witherby S, Rizack T, Sakr BJ, Legare RD, Sikov WM.

Semin Radiat Oncol. 2016 Jan;26(1):59-70. doi: 10.1016/j.semradonc.2015.09.005. Epub 2015 Sep 4. Review.


Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers.

Varadan V, Kamalakaran S, Gilmore H, Banerjee N, Janevski A, Miskimen KL, Williams N, Basavanhalli A, Madabhushi A, Lezon-Geyda K, Bossuyt V, Lannin DR, Abu-Khalaf M, Sikov W, Dimitrova N, Harris LN.

Int J Cancer. 2016 Feb 1;138(3):747-57. doi: 10.1002/ijc.29808. Epub 2015 Aug 31.


How high a bar to change neoadjuvant therapy for triple-negative breast cancer?

Kuritzky B, Sikov WM.

J Comp Eff Res. 2015 Aug;4(4):293-6. doi: 10.2217/cer.15.29. No abstract available.


Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).

Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, Somlo G, Hudis C, Winer E, Ollila DW; Alliance for Clinical Trials in Oncology.

Ann Surg. 2015 Sep;262(3):434-9; discussion 438-9. doi: 10.1097/SLA.0000000000001417.


Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance).

Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, Martino S, Sikov W, Michaelson R, Mardis E, Perou CM, Ellis M, Winer E, Hudis CA, Berry D, Barry WT.

J Natl Cancer Inst. 2015 Jun 25;107(9). pii: djv179. doi: 10.1093/jnci/djv179. Print 2015 Sep.


I will recommend a clinical trial-if I can.

Sikov WM.

Am Soc Clin Oncol Educ Book. 2015:44-6. doi: 10.14694/EdBook_AM.2015.35.44. No abstract available.


Relevance of pCR in breast cancer trials.

Sikov WM.

Oncology (Williston Park). 2014 Oct;28(10):884, 886. No abstract available.


Assessing the role of platinum agents in aggressive breast cancers.

Sikov WM.

Curr Oncol Rep. 2015 Feb;17(2):3. doi: 10.1007/s11912-014-0428-7. Review.


Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.

Castillo JJ, Reagan JL, Sikov WM, Winer ES.

Br J Haematol. 2015 May;169(3):352-5. doi: 10.1111/bjh.13300. Epub 2015 Jan 22.


Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE Study.

Perez K, Safran H, Sikov W, Vrees M, Klipfel A, Shah N, Schechter S, Oldenburg N, Pricolo V, Rosati K, Dipetrillo T.

Am J Clin Oncol. 2017 Jun;40(3):283-287. doi: 10.1097/COC.0000000000000149.


Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP.

J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4.


Dual HER2-targeting without chemotherapy and estrogen deprivation in the neoadjuvant setting.

Sikov WM.

Gland Surg. 2014 Feb;3(1):81-4. doi: 10.3978/j.issn.2227-684X.2013.09.01.


Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.

Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL.

BMC Cancer. 2014 May 8;14:326. doi: 10.1186/1471-2407-14-326.


Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response.

Kern P, Kalisch A, Kolberg HC, Kimmig R, Otterbach F, von Minckwitz G, Sikov WM, Pott D, Kurbacher C.

Chemotherapy. 2013;59(5):387-94. doi: 10.1159/000362756. Epub 2014 May 13.


Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: application and outcomes.

Migdady Y, Sakr BJ, Sikov WM, Olszewski AJ.

Breast. 2013 Oct;22(5):793-8. doi: 10.1016/j.breast.2013.02.014. Epub 2013 Mar 13.


Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study.

Olszewski AJ, Migdady Y, Boolbol SK, Klein P, Boachie-Adjei K, Sakr BJ, Sikov W, Shao T.

Breast Cancer Res Treat. 2013 Feb;138(1):215-23. doi: 10.1007/s10549-013-2423-3. Epub 2013 Jan 26.


Clinical trials in triple negative breast cancer.

Reeder-Hayes KE, Carey LA, Sikov WM.

Breast Dis. 2010;32(1-2):123-36. doi: 10.3233/BD-2010-0310. Review.


Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.

Reagan JL, Rosmarin A, Butera JN, Nadeem A, Schiffman FJ, Sikov WM, Winer E, Mega AE.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1075-80. doi: 10.1007/s00280-011-1702-0. Epub 2011 Jul 15.


Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.

Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E.

Eur J Cancer. 2011 Mar;47(5):683-9. doi: 10.1016/j.ejca.2010.11.024. Epub 2011 Feb 14.


Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer.

Merriam P, Sikov WM.

Breast Cancer (Dove Med Press). 2011 Oct 26;3:139-50. doi: 10.2147/BCTT.S12150. Review.


Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.

Dipetrillo T, Pricolo V, Lagares-Garcia J, Vrees M, Klipfel A, Cataldo T, Sikov W, McNulty B, Shipley J, Anderson E, Khurshid H, Oconnor B, Oldenburg NB, Radie-Keane K, Husain S, Safran H.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):124-9. doi: 10.1016/j.ijrobp.2010.08.005. Epub 2010 Oct 13.


Primary systemic amyloidosis and persistent pleural effusions.

Schwarz D, Jue C, Sikov W.

Amyloid. 2009 Dec;16(4):239-42. doi: 10.3109/13506120903421900.


Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.

Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, Gass JS, Kennedy TA, Fenton MA.

J Clin Oncol. 2009 Oct 1;27(28):4693-700. doi: 10.1200/JCO.2008.21.4163. Epub 2009 Aug 31.


'Weighing in' on screening mammography.

Berz D, Sikov W, Colvin G, Weitzen S.

Breast Cancer Res Treat. 2009 Apr;114(3):569-74. doi: 10.1007/s10549-008-0037-y. Epub 2008 May 20.


Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.

Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN.

J Clin Oncol. 2005 Sep 1;23(25):5983-92. Epub 2005 Aug 8.


A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma.

Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy T.

Cancer. 2002 Nov 1;95(9):2000-5.


Locally advanced breast cancer.

Sikov WM.

Curr Treat Options Oncol. 2000 Aug;1(3):228-38. Review.


Web alert.

Sikov WM, Said BM.

Curr Oncol Rep. 1999 Sep;1(1):3-4. No abstract available.


Splenosis presenting as occult gastrointestinal bleeding.

Sikov WM, Schiffman FJ, Weaver M, Dyckman J, Shulman R, Torgan P.

Am J Hematol. 2000 Sep;65(1):56-61. Review.


Spontaneous venous thrombosis in a young patient with combined factor V Leiden and lupus anticoagulant.

Lopez FF, Sweeney JD, Blair AJ, Sikov WM.

Am J Hematol. 1999 Sep;62(1):58-60.


Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia.

Warkentin TE, Sikov WM, Lillicrap DP.

Am J Hematol. 1999 Sep;62(1):44-8. Review.


A multimodal approach in the diagnosis of patients with hematopoietic disorders.

Mark HF, Gray Y, Mark Y, Khorsand J, Sikov W.

Cancer Genet Cytogenet. 1999 Feb;109(1):14-20.


Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.

Akerley W, Sikov WM, Cummings F, Safran H, Strenger R, Marchant D.

Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-87-S17-90.


Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial.

Akerley W, Choy H, Safran H, Sikov W, Rege V, Sambandam S, Wittels E.

Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-10-S12-13.


Supplemental Content

Support Center